In genome-wide association studies (GWAS), it is a common practice to impute the genotypes of untyped single nucleotide polymorphism (SNP) by exploiting the linkage disequilibrium structure among SNPs. The use of imputed genotypes improves genome coverage and makes it possible to perform meta-analysis combining results from studies genotyped on different platforms. A popular way of using imputed data is the ''expectation-substitution'' method, which treats the imputed dosage as if it were the true genotype. In current practice, the estimates given by the expectation-substitution method are usually combined using inverse variance weighting (IVM) scheme in meta-analysis. However, the IVM is not optimal as the estimates given by the expectation-substitution method are generally biased. The optimal weight is, in fact, proportional to the inverse variance and the expected value of the effect size estimates. We show both theoretically and numerically that the bias of the estimates is very small under practical conditions of low effect sizes in GWAS. This finding validates the use of the expectation-substitution method, and shows the inverse variance is a good approximation of the optimal weight. Through simulation, we compared the power of the IVM method with several methods including the optimal weight, the regular z-score meta-analysis and a recently proposed ''imputation aware'' meta-analysis method (Zaitlen and Eskin [2010] Genet Epidemiol 34:537-542). Our results show that the performance of the inverse variance weight is always indistinguishable from the optimal weight and similar to or better than the other two methods. Genet. Epidemiol. 2011.
INTRODUCTION
The advance of high-throughput technology makes it possible to genotype hundreds of thousands of single nucleotide polymorphisms (SNPs) simultaneously which allows researchers to examine genetic variation across the whole genome in genome-wide association studies (GWAS). By testing the association between SNPs and complex traits and diseases, GWAS have successfully uncovered hundreds of novel susceptibility loci to date [Hindorff et al., 2009] .
Even though current GWAS platforms include markers for hundreds of thousands or even millions of SNPs, they still only directly assay a proportion of the whole genome. Obviously, if only directly genotyped SNPs are considered, this can lead to associated SNPs undetected. Another drawback of the partial coverage is that the selected SNP panel often varies for different platforms [Barrett and Cardon, 2006] . When different studies use different platforms, combining across studies will lead to a much reduced set of SNPs genotyped in all the studies. For example, the overlap between the Affymetrix SNP Array 6.0 and Illumina OmniExpress genotyping array is less than 30%. An effective approach to overcome the aforementioned problems is to impute the untyped SNPs based on a common reference panel.
The basic idea behind genotype imputation is to take advantage of the linkage disequilibrium (LD) information among SNPs. Because of the LD and haplotype structure, genotyped variants can provide information about untyped SNPs. It is feasible to use data on genotyped SNPs along with an appropriate reference panel containing information on a larger set of SNPs to predict the genotypes of the ungenotyped SNPs. Currently, the HapMap project [The International HapMap Consortium, 2005 provides such reference panels, and future studies are likely to extend to the 1,000 Genomes Project [The 1,000 Genomes Project Consortium, 2010] or other whole genome or exome sequence data. The most popular imputation programs include MACH [Li et al., 2010] , IMPUTE [Marchini et al., 2007] , and Beagle [Browning and Browning, 2009 ], among others.
There are several approaches to using imputed values in the association analysis. Suppose a SNP of a given subject i has genotype g i , where g i takes one of the three values 0, 1, r 2011 Wiley-Liss, Inc. and 2, the number of copies of one of the alleles (typically the ''minor'' or lower frequency allele). The output of an imputation program usually includes three probabilities: p i0 5 P(g i 5 0); p i1 5 P(g i 5 1); p i2 5 P(g i 5 2). One method is to use the most likely genotype (the genotype with the highest probability) as if it were the true genotype. However, it has been shown in Lin and Huang [2007] that this method leads to intrinsically biased estimates because of the unavoidable discrepancy between the most likely genotype and the true genotype. Another popular approach is the so-called expectation-substitution method. Instead of using the most likely genotype, this method uses the dosages, expected number of minor alleles 5 p i1 12p i2 , as if it were the true genotype. In the haplotype analysis framework, several studies [Kraft et al., 2005; Kraft and Stram, 2007; Cordell, 2006] have shown through a series of simulation experiments that the expectation-substitution method has no noticeable bias under practical settings. It is also possible to use Bayesian methods [Marchini et al., 2007; Servin and Stephens, 2007] to perform the imputation and the association test at the same time, however, these methods are usually computationally intensive and hence not feasible on a genome wide scale. Therefore, in the remaining of the article, we will focus on the expectation-substitution method.
If multiple studies are imputed using the same reference, then the different studies have data on a common set of SNPs, making meta-analysis across studies possible. Because combining studies increases sample size, meta-analysis increases power and allows detection of loci not found in individual studies. One way of performing meta-analysis is to use the regular z-score meta-analysis (MetaZ), which combines z-scores weighted by square root of sample sizes. Alternatively, the effect size meta-analysis (MetaBeta) combines effect sizes by computing a weighted average of the estimates. For meta-analysis that involves imputed genotypes, the imputation quality is an important factor. Hence, it seems natural that the imputation quality should also be reflected in the weight for meta-analysis.
For MetaZ, de Bakker et al. [2008] suggested scaling the weighted sum of z-scores by the imputation quality measure. Based on this idea, Zaitlen and Eskin [2010] have recently proposed an ''imputation aware'' method to combine z-scores. In the ''imputation aware'' method, the weight for the z-score of each study is proportional toR ffiffiffi n p , where R 2 is the imputation quality measure and n is the sample size. Results has shown the ''imputation aware'' method is more powerful than the regular z-score metaanalysis when the imputation quality varies among studies [Zaitlen and Eskin, 2010] .
For MetaBeta, most studies use the traditional inverse variance weighting (IVM) to combine estimates from imputed and genotyped SNPs in current practice [Soranzo et al., 2009; Willer et al., 2008] . However, it is unknown whether the IVM is the optimal weighting scheme under this situation. In this article, we address this question. For imputed SNPs, we find that the optimal weight is proportional to both the expected value and inverse variance of estimates given by the expectation-substitution method. While the expectation-substitution method does not give unbiased estimators in general, the bias is usually very small under practical situations of GWAS. Based on this finding, we show that the inverse-variance weighting scheme is a good approximation of the optimal weight for the meta-analysis of imputed SNPs. These results are important, because they validate that the expectationsubstitution method and the IVM scheme currently being used in GWAS meta-analysis are adequate and close to be optimal in GWAS settings.
MATERIALS AND METHODS

MODELS
Consider a case-control study of n individuals. For a given SNP, suppose for subject i, i ¼ 1; . . . ; n, the true genotype is g i 5 0, 1, or 2 and the disease status is d i 5 0 or 1, where 0 indicates control and 1 indicates case, then the standard logistic model for modeling the association between the SNP and disease status is:
Note that model (1) is designed for a prospective study where subjects are first selected, then followed up for disease development. However, in many GWAS, the study design is retrospective. In a seminal article by Prentice and Pyke [1979] , the authors showed that it is valid to apply model (1) to a case-control study as if the data were prospectively collected and the resulting estimators of b 1 are consistent to the true values and asymptotically normal. Because of its simplicity and the appealing interpretation of exp(b 1 ) which approximates relative risk in rare disease, model (1) has been widely used in practice and will be used throughout this article.
If the genotype for this given SNP is unknown, the expectation-substitution method replaces the unknown genotype by the dosage from the imputation g i ¼ p i1 12p i2 . In this case, model (1) becomes
The likelihood function can be written as:
By Taylor's expansion, the maximum likelihood estimator ðb 0 ;b 1 Þ for (b 0 ,b 1 ) satisfies
where Taking the expectation of U(b 0 ,b 1 ) in Equation (4), we have
When b 1 5 0 (no association) or one of p i0 , p i1 , p i2 is 1 (perfectly imputed), it is obvious that
andb 1 is unbiased. Therefore, the expectation-substitution method does not cause potential inflation in type I error rate. On the other hand, if b 1 6 ¼ 0 and the imputation is imperfect,b 1 from (4) is biased, which as we show below, could cause potential problems.
OPTIMAL WEIGHT FOR META-ANALYSIS WITH IMPUTED VALUES
Suppose for a given imputed SNP, the b 1 ð6 ¼ 0Þ estimate from (4) in the ith study (i ¼ 1; . . . ; M) isb i 1 ; the estimated variance forb i 1 isV i ; the weight for the ith study is w i , then the estimate for b 1 from the meta-analysis iŝ
Based on (8), the optimal weight to maximize the power to detect the association is equivalent to maximizing
A simple derivation shows that w i needs to be proportional to m i /V i in order to maximize (9). Hence, even if the effect size is the same across studies, m i may still vary among studies because variation in imputation quality between studies will yield a different degree of bias in b 1 estimates. This contrasts to the directly genotyped data where m i 5 b 1 for all studies so w i needs to only be proportional to 1=V. However, this optimal weight which incorporates both the variance and m i is hard to estimate in practice, because of the difficulty in estimating m i .
Fortunately, we can show theoretically that the bias of b 1 is very small when the true b 1 is small, regardless of the imputation quality. Given the approximate unbiasedness of b 1 estimators, the optimal weight can therefore be approximated by the regular inverse variance weight.
INVERSE VARIANCE INCORPORATES IMPU-TATION QUALITY
We have shown the inverse variance weight can approximate the optimal weight. For imputed SNPs, it seems natural that the weight forb 1 should increase as imputation quality increases. For this reason, we will explore whether the IVM scheme incorporates imputation quality. In the expectation-substitution method, the variance of ðb 0 ;b 1 Þ 0 can be estimated by
The first derivative of hðg;b 0 ;b 1 Þ with respect to g iŝ b 1 expðb 0 1b 1 gÞf1À expðb 0 þb 1 gÞg=½ð11 expfb 0 þb 1 gÞg 3 , which is approximately 0 whenb 1 is sufficiently small. Hence, we can consider hð g i ;b 0 ;b 1 Þ as a constant c, and write Equation (10) as
where R 2 is the imputation quality measure in MACH [Li et al., 2010] defined as the ratio of the sample variance of g i and the expected variance of g i , which is equivalent to the squared correlation between true and imputed genotypes. From Equation (11), we can see that the inverse variance of b 1 is approximately proportional to the imputation quality. Thus, we show that the current IVM scheme automatically incorporates imputation quality in the meta-analysis. Simulation results confirm the positive correlation between the imputation quality and inverse variances (see Results section).
Another interesting observation is that there is a connection between the IVM scheme and the ''imputation aware'' method in Zaitlen and Eskin [2010] through (11). Note that the IVM estimator can be written as
and the ''imputation aware'' method can be written as
We can see that the only difference between (12) and (13) is the var(g i ) part. Since var(g i ) depends on minor allele frequency (MAF), we expect those two methods perform similarly when the MAFs of the SNP across studies are similar. Generally, we do not expect the MAF varies much for studies with similar ethnicity. However, if meta-analysis was conducted across different ethnic groups [Xiong et al., 2009; Chapman et al., 2008] , the MAF variation can be substantial. In such cases, we expect the IVM method to have better power.
RESULTS
In this section, we first use simulation to demonstrate the finite sample properties ofb 1 given by the expectationsubstitution method, such as the approximate unbiasedness and relationship between varðb 1 Þ and imputation quality. Then, we compare the power of the IVM method in the meta-analysis with various other methods.
FINITE SAMPLE PROPERTIES OFb 1
Simulation situations. We generated the genotypes of two SNPs, considering a range of MAF combinations (f 1 ,f 2 ) of the two SNPs, and a range of LD measure as D 0 . To mimic the imputation scenario, we assume that genotypes of the second SNP are unknown, and imputed its dosage based on the genotypes of the first SNP. We varied the imputation quality by changing the LD measure D 0 . A population of 10,000 was generated based on the logistic regression model in Equation (1) with genotypes at the second SNP as the g i 's, b 0 5 0, and b 1 ¼ logð1:2Þ; logð1:5Þ; logð2Þ, corresponding to odds ratios 1.2, 1.5, and 2. Then 1,000:1,000 case-control samples were randomly selected from this population of 10,000. We fit model (2) to the case-control samples with the imputed dosage at the second SNP as g i . For comparison, we also fitted model (1) with the true genotype g i . For each parameter setting, we replicated the above procedure 10,000 times. The results are summarized in Table I .
When b 1 5 0, all the estimated type I error rates are well controlled at the nominal a level 0.05. When b 1 5 log(1.2) and log(1.5), the relative bias ofb 1 is very small (o2%), regardless of the MAF of both SNPs. In contrast, when b 1 is b 1 is the true value; f 1 and f 2 are the MAFs for SNP 1 (the marker) and 2 (the disease-causing SNP with missing genotypes), respectively; D 0 is the LD measure; Bias (%) is the percentage of relative bias (100ðEðb 1 Þ À b 1 Þ=b 1 ); SE and SD are standard error and standard deviation estimates ofb 1 from 10,000 replicates, respectively; 95% CP is the estimated coverage probability for the 95% confidence interval; R 2 is the imputation quality measure; Power is obtained at a significance level of 0. larger, log(2),b 1 slightly underestimates the true b 1 and the bias is greater as the imputation quality worsens. Under the simulation settings in Table I, 
Figure 1 shows that even with the worst imputation quality in Table I (when D 0 5 0.5), the bias ofb 1 is still less than 5% for the odds ratio as large as 2. Since it is less common for the associated alleles identified by GWAS to have an odds ratio greater than 2 [Hindorff et al., 2009 [Hindorff et al., , 2011 , this bias is not really problematic in GWAS settings.
In Table I , the mean of standard errors (SE) and the standard deviation (SD) of the estimates over 10,000 simulated data sets agree with each other very well, suggesting that the SE estimates are reliable. Furthermore, the SE ofb 1 decreases as the imputation quality R 2 increases; as a result, the power (Power) increases. As a comparison, we also show the standard deviations of parameter estimates (SD Ã ) and power (Power Ã ) if the genotypes for SNP 2 are known. As we can see, SD Ã is always less than SD and Power Ã is always greater than Power, which implies that there is efficiency loss using imputed genotypes. For example, when b 1 5 log(1.2) and f 1 5 f 2 5 0.2, the power loss decreases from 67% to 0.6% as the imputation quality increases. Taken together, we can see that even with very small R 2 , the power is still acceptable in many cases using imputed genotypes. The estimated coverage probabilities are all very close to the nominal value 0.95, indicating that the confidence interval estimates are very accurate.
Real imputation data. In order to explore the performance of the expectation-substitution method in a more realistic setting, we used GWAS scans from Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) [Prorok et al., 2000; Hayes et al., 2000] . PLCO is a randomized, two-arm trial coordinated by the NCI in 10 US centers.
The PLCO data include 2,520 samples, genotyped on Illumina Human Hap 300 k&240 k, 550 k and 610 k platforms. We randomly selected 1,000 genotyped SNPs on chromosome 22 and masked their genotypes. Then we used MACH to impute the genotypes of the 1,000 SNPs as if they were untyped, using HapMap II release 24 as the reference panel. In this way, we have both the true genotypes and the imputed dosages. Similarly, as in the previous section, case-control samples were generated based on model (1) using true genotypes andb 1 was estimated by fitting the model (2) with imputed dosages. We set b 1 to be 0, log(1.2), log(1.5), and log(2). For each value of b 1 , we replicate the procedure 50 times for each of the 1,000 SNPs. Figure 2 shows a boxplot of the percent of bias ofb 1 of SNPs grouped by MAF and R 2 . We can see that b 1 is approximately unbiased regardless of the imputation quality R 2 , which agree with the theoretical results. On the other hand, the variability of the estimates is much greater when R 2 o0.3 and MAFo0.05.
PERFORMANCE OF IVM IN THE META-ANALYSIS
We generated the data in the same way as the previous section. Here, we let b 1 take 10 equally spaced values from 0.05 to log(2), MAFs (f 1 ,f 2 ) of the two SNPs be (0.2,0.2) for both studies and the LD measure D 0 0.5 and 0.99 for two studies, respectively. We conducted meta-analysis for the two studies using the following four methods and compared their power:
1. The optimal weighting, which is proportional to m i =V i .
In practice, it is usually impossible to estimate m i . However, with b 1 ,f 1 ,f 2 and D 0 known in the simulation, we can compute m i from (14). Hence, we can estimate the optimal weight for the purpose of comparison. 2. The IVM method, which is an approximation of the optimal weighting under practical situations in GWAS. 3. The ''imputation aware'' method by Zaitlen and Eskin [2010] . 4. The regular z-score meta-analysis (MetaZ) method without correcting for imputation quality. As we can see from Figure 3 , the optimal weighting, IVM and the ''imputation aware'' method have indistinguishable performance. In addition, they are all more powerful than the regular MetaZ method which does not account for imputation quality. This confirms that the IVM method is a good approximation of the optimal weight and it automatically incorporates the imputation quality.
We also simulated a situation where the MAFs are different between the two studies, which results in different var(g i ). Instead of letting the MAF 5 0.2 for both studies, we let the MAF 5 0.1 for the first study and 0.4 for the second study. The power comparison is shown in Figure 4 . As we expected, the IVM method has better performance than the ''imputation aware'' method in this case because it is an approximation to the optimal weight. In practice, we would not expect MAFs differ substantially for studies of similar populations. However, for a crossethnicity meta-analysis, the IVM is superior to the ''imputation aware'' method since it accounts for the MAF variation among different ethnic groups.
DISCUSSION
As imputation has been widely used to recover information from GWAS data, the expectation-substitution method is the most commonly used method to analyze imputed SNPs while accounting for genotype uncertainty. Our work shows, both numerically and theoretically, that the expectation-substitution method gives approximately unbiased estimates under practical conditions of low effect sizes for GWAS studies of common diseases. We also show that the IVM scheme approximates the optimal weight well and always has the best power among different metaanalysis methods compared.
Two recent articles have outlined the advantages of using meta-analysis, and discussed study design, quality control, and analysis issues to consider when implementing meta-analysis of GWAS data [Cantor et al., 2010; Zeggini and Ioannidis, 2009] . These articles address weighting schemes for combining results, but focus more on random-effects vs. fixed-effects analysis, rather than on methods to include imputation quality.
The different imputation software packages provide information not only on the probability of each genotype but also an overall imputation quality measure. This measure is typically defined as the ratio of the sample variance of the genotype to the expected variance, with lower scores indicating less well-imputed SNPs. Studies often exclude SNPs with either low R 2 or low MAF. A threshold of imputation R 2 5 0.3 has been recommended by MACH as the imputation quality cut-off for estimates [MACH Homepage]. Our results show that in terms of bias, the combination of imputation quality and MAF seems to be most relevant. In particular, we show that the variability of estimates is large for lower imputation quality and lower MAF. In current practice, rare variants (MAFo0.05) are often excluded from imputation and subsequent meta-analysis. In this situation, either not using a filter, or using a filter based only on R 2 is likely sufficient. However, as meta-analysis grows larger and data become available to impute rare variants, we recommend using both the imputation quality and the MAF to set filtering criterion. For example, in our simulation results (Fig. 2) , the optimal filter appears to be excluding SNPs with both MAFo0.05 and R 2 o0.3, rather than all SNPs with R 2 o0.3. In this article, we used the imputation quality measure R 2 defined by MACH [Li et al., 2010] , which is the squared correlation between true genotypes and imputed dosages. In Beagle [Browning and Browning, 2009] . It turns out that the two R 2 's are highly correlated (r40.99). Thus, although the cut-offs for the two R 2 's could be slightly different, the general conclusion should still hold.
As we move into the post-GWAS era, our results provide important guidance for investigators on how to optimally conduct meta-analysis in the presence of imputed genotypes for marginal SNP associations. We support the current practice of using the expectationsubstitution method and the IVM in meta-analysis. Additional theoretical and numerical work is needed to evaluate the use of imputed data in more sophisticated analysis, including proposed methods for gene-gene and gene-environment interactions.
gap through dbGaP accession number ph000093 v2.p2.c1. In addition, data generated from the Cancer Genetic Markers of Susceptibility (CGEMS) [CGEMS] prostate cancer scan were also included in this analysis. The data sets used for the analyses described in this manuscript were accessed with appropriate approval through the dbGaP online resource (http://www.cgems.cancer.gov/data) through dbGaP accession number 000207 v.1p1.c1. 
Proof
Applying Lemma 2, whenb 1 ! b 1 1dðb 0 ; b 1 Þ, the LHS of Equation (A4) will be positive; whenb 1 b 1 À dðb 0 ; b 1 Þ, the LHS of Equation (A4) will be negative. As the LHS of Equation (A4) is also an increasing function ofb 1 , then the root of Equation (A4) b
